en es es es es es en pt es en es en en en es es fr en es es fr es es es es es es en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en es es en en en en en es es es es es es es es pt pt pt en es es en es es es es es en es gl es es es es en es es es es en es es es es es es es es en es es es gu es
Las Terapias CAR T se mantiene como la gran promesa para pacientes con cánceres hematológicos de difícil tratamiento.
Para personas con ciertos tipos de cánceres hematológicos  agresivos y refractarios, las opciones de tratamiento son muy  limitadas. Pero tres estudios presentados el pasado Domingo  en la 59ª Reunión  Anual de la Sociedad Americana de Hematología (ASH) en Atlanta destacan el papel emergente desempeñado por los receptores de antígenos quiméricos (CAR) en las terapias de células T para ayudar a las personas a desarrollar una respuesta clínica y, en algunos casos , lograr una remisión duradera.
Estas terapias se diseñan recolectando las células T propias del paciente (las células principales que matan el cáncer del sistema inmune) reinyectándolas para identificar proteínas específicas en la superficie de la leucemia y células de linfoma, y ​​reintroduciendo las células T modificadas en la inmunidad del paciente sistema.
En dos análisis de seguimiento separados a más largo plazo (de los ensayos ZUMA-1 y JULIET), los investigadores encontraron que las respuestas iniciales se mantuvieron en el tiempo en pacientes que recibieron células T genéticamente modificadas diseñadas para frente a CD-19, que es frecuentemente expresado en células de linfoma maligno. Un tercer estudio de fase I, uno de los más grandes para evaluar una terapia CAR dirigida a BCMA, un marcador presente en la gran mayoría de las células tumorales de mieloma múltiple, mostró resultados iniciales alentadores en pacientes con mieloma múltiple muy pretratados.
Responses to CAR T-Cell Therapy Still Strong after One Year in Patients with Refractory NHL, Data also Shed Light on Why Therapy Fails in Some Patients
Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Among 108 patients with fast-growing and refractory aggressive non-Hodgkin lymphoma (NHL), more than half were still alive at least a year after receiving a single infusion of a CAR T-cell therapy, axicabtagene ciloleucel (axi-cel), that targets the CD-19 protein frequently found on cancerous lymphoma cells, researchers reported. This latest analysis of ZUMA-1, which combines Phase I and II trial data, assessed the rate and durability of responses and survival among these patients after a median follow-up of 15.4 months. More than one year after a single infusion of axi-cel, 42 percent of patients remain in remission and 40 percent of patients exhibit no evidence of cancer.
“Long-term follow-up of ZUMA-1 confirms that these responses can be durable and the ongoing responses at 24 months suggest that late relapses are uncommon. Patients who are in remission at 6 months tend to stay in remission,” said lead study author Sattva S. Neelapu, MD, professor at The University of Texas MD Anderson Cancer Center. “With existing therapy, the median survival for people with this disease is only 6 months. Here, we see more than half of patients — 59 percent — are still alive over a year after treatment.”
The study, which is being conducted at 22 sites, is the largest study of a CAR T-cell therapy’s efficacy to date, according to researchers. Dr. Neelapu explains that the durability findings are also consistent with observations from earlier, single-institution trials of axi-cel in this patient population. In terms of safety, no new deaths related to the therapy occurred. Early in the study, four patients died within two months of treatment — two attributable to the CAR T-cell therapy and the other two to unrelated adverse side effects that are typical of disease progression. In the pivotal portion of ZUMA-1, common adverse events consisted of CRS, neurologic toxicities, neutropenia, anemia, and thrombocytopenia. Ten patients experienced a serious adverse event six months after the primary analysis, including infections in eight patients. No new onset CRS or neurologic events related to axi-cel were observed in the updated analysis.
The study also provides some of the first clues as to why some patients relapse or do not respond to CAR T-cell therapy After analyzing tumor tissue from before and after treatment in patients who relapsed, the researchers found that in a third of patients the CD19 protein was no longer present on cancer cells. Secondly, more than two-thirds of tumors showed evidence of another protein, PD-L1, likely helping the cancer cells survive by inhibiting the function of the infused T cells. Follow-up studies are now underway to identify possible approaches to overcoming these problems.
There are roughly 72,000 new cases of NHL in the U.S. each year. NHL starts in white blood cells called lymphocytes, which are part of the immune system. There are two main types of lymphocytes — B-cells and T-cells — whose role is to help the body fight infection.
A randomized trial to compare the efficacy of this therapy with second-line standard of care, which includes autologous stem cell transplantation for relapse after first-line therapy, is planned in patients with aggressive B-cell NHL.
Funding for this study was provided by Kite Pharma, Inc., now Gilead Sciences.
Six-Month Analysis of Tisagenlecleucel in Stubborn Form of Lymphoma Shows Sustained Responses
Primary Analysis of Juliet: A Global Pivotal Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Six months after receiving a single dose of tisagenlecleucel, a CAR T-cell therapy that targets CD-19, high response rates persist among adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to researchers.
This latest interim analysis of the international JULIET trial showed that for 46 patients with at least 6 months of follow-up, the overall response rate was 37 percent, with 30 percent achieving a complete response and 7 percent achieving a partial response. What’s more, according to researchers, this observation indicates that, among 81 patients treated, those whose signs of cancer had gone away at 3 months remained relapse-free at 6 months and beyond.
“While we don’t completely understand why these remissions are so durable, it’s exciting and will change how this disease is treated when conventional therapies fail,” said lead study author Stephen Schuster, MD, Professor of Hematology/Oncology in the Perelman School of Medicine at the University of Pennsylvania (Penn) and Penn’s Abramson Cancer Center. “We are going to be able to offer patients who don’t respond to standard therapies a form of therapy that may, after a single treatment, relieve symptoms and save lives.”
DLBCL is the most common form of lymphoma, accounting for roughly one-third of all non-Hodgkin lymphoma cases. While current therapy is successful for many people with this disease, those not responding to current treatments face a poor prognosis with limited treatment options. According to Dr. Schuster, primary therapy will fail in about one-third of people with DLBCL, and half of these patients will not be candidates for stem cell transplantation, which is considered the best second-line treatment approach; such patients would be candidates for this type of therapy.
This single-arm, open-label Phase II trial is the largest study examining a CAR T-cell therapy exclusively in people with DLBCL. It is being conducted at 27 sites spanning 10 countries across North America, Europe, Australia, and Asia. Enrollees had received two or more lines of prior chemotherapy and had disease progression, or had failed to respond or were ineligible for autologous stem cell transplant. Patients ranged in age from 22 to 76 years old.
Subgroup analyses showed no difference in outcomes based on prior DLBCL treatment or risk factors. Of the 81 patients included in JULIET, the responding patients continue to be followed without any additional therapy, and median durable overall response and overall survival have yet to be reached.
Most of the adverse events were seen shortly after infusion and included CRS and neurotoxicities. There were no deaths attributable to CTL019, CRS, or neurological events.
Dr. Schuster said several factors set this trial apart from other investigations of CAR T-cell therapies, including that the therapy was done on an outpatient basis for many patients (26 percent) and the manufacturing process allowed investigators to generate CAR T cells from previously collected and frozen blood cells, permitting successful shipment around the world.
“Once the CAR T cells were generated, we could freeze them again, allowing us to hold the product until patients were clinically ready to receive them,” he said. “These are very sick patients, so this gives the treating physician some flexibility to schedule therapy when it’s best for each patient.”
Patients in the JULIET trial who responded to therapy continue to be followed carefully for recurrence of their lymphoma and recovery of their immune system.
Funding for this study was provided by Novartis.
Clinical Activity Seen with Anti-BCMA CAR T-Cell Therapy in Phase 1 Study of People with Heavily Pre-Treated Multiple Myeloma
Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-BCMA CAR-T Cell Therapy
A one-time infusion of an investigational CAR T-cell therapy that targets a protein found on most multiple myeloma cells elicited an 86-percent overall response rate in 21 patients whose disease had come back or had not responded after a median of seven prior treatments, according to results from a Phase I study.
Among 18 patients who received higher, active doses of infused CAR T cells, this response rate increased to 94 percent, with manageable adverse effects, researchers reported. Among these 18 patients, 10 achieved a complete response and 9 of 10 evaluated for minimal residual disease (MRD) using sensitive genetic tests achieved an MRD-negative response. After a median follow-up period of 40 weeks, the median progression-free survival had not been reached; four patients who received active doses had seen their disease get worse.
“We are excited about the early results in a patient population with very advanced myeloma for whom previous therapies have failed,” said senior study author James N. Kochenderfer, MD, of the Center for Cancer Research at the National Cancer Institute in Bethesda, Maryland.
These findings are important, Dr. Kochenderfer said, because despite recent therapeutic advances, multiple myeloma — a cancer that begins in plasma cells, cells in the bone marrow that help the body fight infection — remains nearly incurable. Existing therapies require patients to stay on treatment long-term with drugs that have side effects, he said.
“CAR T-cell therapy is completely different from other available treatments for multiple myeloma,” Dr. Kochenderfer said. “We have patients who have a sustained response and have been able to go for over a year with no additional myeloma therapy and tolerable adverse effects.”
The study, conducted at nine sites in the United States, is the first U.S.-based multicenter study of a CAR T-cell therapy engineered to target BCMA, a protein found on the vast majority of both myeloma tumor cells and normal plasma cells, but no other healthy tissues. An estimated 30,000 people in the United States will be diagnosed with multiple myeloma in 2017.
Twenty-one patients with a median age of 58 years were enrolled in the dose-escalation phase of the study. All had seen their disease come back or stop responding after a median of seven prior treatments, including a stem cell transplant.
The primary objective of the Phase I study was to identify the “maximum tolerated dose” of the experimental treatment — that is, the highest dose that could be given without unacceptable levels of adverse effects. Additional outcome measures included evaluating whether any cancer cells remained in the bone marrow, the length of time until the cancer began to get worse, and response to treatment as measured by a standard set of criteria for assessing multiple myeloma.
Most patients experienced adverse effects, including low blood counts, CRS, and neurologic symptoms. All three patients treated at an inactive CAR-T dose, the lowest dose in the dose-escalation stage of the trial, died from progression of their myeloma within one year. Among the 18 patients treated at active CAR-T doses, two patients died from other causes while their myeloma was in a complete response to CAR-T therapy.
These findings are preliminary and, as a Phase I trial, the study had no control group and was designed primarily to identify a safe dose of bb2121, not to evaluate the drug’s effectiveness.
Funding for this multi-site study was provided by Celgene Corporation and bluebird bio, Inc.
Posicionamiento sobre la terapia con células T CAR en España
Whole-exome sequencing in clinical genetics : A health economic evaluation
Accurate lymphoma/leukemia diagnosis is the key for precision medicine. !6-17 Noviembre, Madrid FJD
Mutaciones en el ADN no codificante protegen al cerebro de la ELA mayo 24, 2022
La amplificación de MET predice el beneficio de la terapia dirigida con crizotinib en NSCLC marzo 16, 2022
Inmunoterapia para el cáncer de cabeza y cuello: un cambio de paradigma de la quimioterapia de inducción a la inmunoterapia neoadyuvante febrero 14, 2022
Estudio prospectivo unicéntrico sobre la eficacia de nivolumab contra el carcinoma de células escamosas de cabeza y cuello recurrente o metastásico, sensible al platino febrero 13, 2022
Los científicos de los NIH construyen un modelo celular de las lesiones de la esclerosis múltiple septiembre 11, 2021
Archivos Elegir el mes mayo 2022 marzo 2022 febrero 2022 septiembre 2021 mayo 2021 abril 2021 marzo 2021 febrero 2021 enero 2021 diciembre 2020 noviembre 2020 septiembre 2020 agosto 2020 julio 2020 junio 2020 mayo 2020 febrero 2020 enero 2020 diciembre 2019 octubre 2019 julio 2019 junio 2019 mayo 2019 abril 2019 marzo 2019 febrero 2019 enero 2019 diciembre 2018 noviembre 2018 octubre 2018 septiembre 2018 junio 2018 abril 2018 febrero 2018 enero 2018 diciembre 2017 agosto 2017 julio 2017 junio 2017 mayo 2017 abril 2017 marzo 2017 febrero 2017
Renovatio es una consultora especializada en el diseño, gestión y desarrollo de proyectos multidisciplinares, formación y comunicación en biomedicina.
Mutaciones en el ADN no codificante protegen al cerebro de la ELA mayo 24, 2022
La amplificación de MET predice el beneficio de la terapia dirigida con crizotinib en NSCLC marzo 16, 2022
Inmunoterapia para el cáncer de cabeza y cuello: un cambio de paradigma de la quimioterapia de inducción a la inmunoterapia neoadyuvante febrero 14, 2022
Inmunoterapia para el cáncer de cabeza y cuello: un cambio de paradigma de la quimioterapia de inducción a la inmunoterapia neoadyuvante
Estudio prospectivo unicéntrico sobre la eficacia de nivolumab contra el carcinoma de células escamosas de cabeza y cuello recurrente o metastásico, sensible al platino
© 2022 Renovatio Biomédica. All rights reserved
Gestionar el consentimiento de las cookies
Para ofrecer las mejores experiencias, utilizamos tecnologías como las cookies para almacenar y/o acceder a la información del dispositivo. El consentimiento de estas tecnologías nos permitirá procesar datos como el comportamiento de navegación o las identificaciones únicas en este sitio. No consentir o retirar el consentimiento, puede afectar negativamente a ciertas características y funciones.
Funcional Funcional Siempre activo
El almacenamiento o acceso técnico es estrictamente necesario para el propósito legítimo de permitir el uso de un servicio específico explícitamente solicitado por el abonado o usuario, o con el único propósito de llevar a cabo la transmisión de una comunicación a través de una red de comunicaciones electrónicas.
El almacenamiento o acceso técnico es necesario para la finalidad legítima de almacenar preferencias no solicitadas por el abonado o usuario.
El almacenamiento o acceso técnico que es utilizado exclusivamente con fines estadísticos. El almacenamiento o acceso técnico que se utiliza exclusivamente con fines estadísticos anónimos. Sin un requerimiento, el cumplimiento voluntario por parte de tu Proveedor de servicios de Internet, o los registros adicionales de un tercero, la información almacenada o recuperada solo para este propósito no se puede utilizar para identificarte.
El almacenamiento o acceso técnico es necesario para crear perfiles de usuario para enviar publicidad, o para rastrear al usuario en una web o en varias web con fines de marketing similares.